Cargando…
Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening
High-throughput screening facilities do not generally support biosafety level 3 organisms such as Mycobacterium tuberculosis. To discover not only antibacterials, but also virulence inhibitors with either bacterial or host cell targets, an assay monitoring lung fibroblast survival upon infection was...
Autores principales: | Tükenmez, Hasan, Edström, Isabel, Ummanni, Ramesh, Fick, Stina Berglund, Sundin, Charlotta, Elofsson, Mikael, Larsson, Christer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328581/ https://www.ncbi.nlm.nih.gov/pubmed/30631100 http://dx.doi.org/10.1038/s41598-018-37176-4 |
Ejemplares similares
-
Invasive Mycobacterium
marinum Infections
por: Lahey, Timothy
Publicado: (2003) -
Adenitis as Initial Mycobacterium marinum Presentation
por: Oliveira e Silva, Fernando, et al.
Publicado: (2023) -
Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection
por: Tian, Wei-wei, et al.
Publicado: (2013) -
Inhibitors of Mycobacterium marinum virulence identified in a Dictyostelium discoideum host model
por: Ouertatani-Sakouhi, Hajer, et al.
Publicado: (2017) -
Arabinogalactan enhances Mycobacterium marinum virulence by suppressing host innate immune responses
por: Li, Ye-yu, et al.
Publicado: (2022)